Article

Reduced intraoperative bleeding during transurethral resection of the prostate: Evaluation of finasteride, vascular endothelial growth factor, and CD34

Current Prostate Reports 04/2012; 6(3):123-127. DOI:10.1007/s11918-008-0019-x pp.123-127

ABSTRACT Finasteride is an antiandrogen that inhibits 5-α-reductase, an enzyme that converts testosterone to dihydrotestosterone. Finasteride
significantly reduces intraoperative bleeding when 10 mg/d is administered for 60 days before transurethral resection of the
prostate. Our double-blind, randomized, placebo-controlled study evaluated 200 patients with benign prostatic hyperplasia
who underwent transurethral resection of the prostate. We compared a placebo group (n = 100) with a group (n = 100) administered 5 mg of finasteride twice a day for 8 weeks. We intended to demonstrate the mechanisms and effects of
finasteride compared with those of vascular endothelial growth factor, and to evaluate CD34, an immunohistochemical marker
of blood vessel density in the prostate. Our results indicated a lower average microvascular density and vascular endothelial
growth factor index for hypertrophic prostate in the finasteride group than in the placebo group.

0 0
 · 
0 Bookmarks
 · 
27 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

8 weeks
 
benign prostatic hyperplasia
 
blood vessel density
 
double-blind
 
finasteride group
 
hypertrophic prostate
 
immunohistochemical marker
 
inhibits 5-α-reductase
 
intraoperative
 
lower average microvascular density
 
placebo group
 
placebo-controlled study
 
prostate
 
transurethral resection
 
vascular endothelial growth factor